Livforsakringsbolaget Skandia Omsesidigt Has $136,000 Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Livforsakringsbolaget Skandia Omsesidigt trimmed its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 73.7% in the fourth quarter, HoldingsChannel reports. The firm owned 1,000 shares of the company’s stock after selling 2,800 shares during the period. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Neurocrine Biosciences were worth $136,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of NBIX. Caprock Group LLC acquired a new stake in shares of Neurocrine Biosciences in the 4th quarter valued at about $236,000. Plato Investment Management Ltd grew its stake in Neurocrine Biosciences by 2,481.9% in the third quarter. Plato Investment Management Ltd now owns 10,973 shares of the company’s stock valued at $1,263,000 after acquiring an additional 10,548 shares during the period. Swiss National Bank increased its holdings in shares of Neurocrine Biosciences by 1.4% during the third quarter. Swiss National Bank now owns 298,700 shares of the company’s stock valued at $34,416,000 after acquiring an additional 4,100 shares in the last quarter. Tri Ri Asset Management Corp acquired a new position in shares of Neurocrine Biosciences during the third quarter worth approximately $3,236,000. Finally, KBC Group NV raised its position in shares of Neurocrine Biosciences by 78.3% during the third quarter. KBC Group NV now owns 18,972 shares of the company’s stock worth $2,186,000 after purchasing an additional 8,332 shares during the period. 92.59% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Bank of America decreased their price target on shares of Neurocrine Biosciences from $184.00 to $179.00 and set a “buy” rating for the company in a research note on Friday. HC Wainwright lowered their target price on shares of Neurocrine Biosciences from $190.00 to $185.00 and set a “buy” rating on the stock in a report on Friday. Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a research note on Friday. BMO Capital Markets lowered their price objective on Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a research note on Thursday, October 17th. Finally, William Blair restated an “outperform” rating on shares of Neurocrine Biosciences in a report on Friday. Five investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and an average price target of $167.81.

Insider Transactions at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 272 shares of the firm’s stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $138.10, for a total value of $37,563.20. Following the completion of the transaction, the insider now owns 2,507 shares in the company, valued at $346,216.70. This trade represents a 9.79 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Kevin Charles Gorman sold 2,707 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $152.92, for a total value of $413,954.44. Following the sale, the director now owns 517,030 shares in the company, valued at approximately $79,064,227.60. This represents a 0.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 222,693 shares of company stock worth $32,718,279 over the last quarter. Corporate insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Price Performance

NASDAQ:NBIX opened at $122.62 on Friday. The company has a market capitalization of $12.42 billion, a P/E ratio of 32.87 and a beta of 0.33. The business has a fifty day simple moving average of $138.89 and a two-hundred day simple moving average of $131.77. Neurocrine Biosciences, Inc. has a 1 year low of $110.95 and a 1 year high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 15.68% and a net margin of 17.21%. As a group, analysts anticipate that Neurocrine Biosciences, Inc. will post 3.92 earnings per share for the current year.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.